中华眼底病杂志
中華眼底病雜誌
중화안저병잡지
CHINESE JOURNAL OF OCULAR FUNDUS DISEASES
2015年
1期
31-35
,共5页
戚沆%陈长征%易佐慧子%周芸芸
慼沆%陳長徵%易佐慧子%週蕓蕓
척항%진장정%역좌혜자%주예예
脉络膜/病理生理学%脉络膜新生血管化/药物疗法%血管生成抑制剂/治疗应用%抗体,单克隆/治疗应用%体层摄影术,光学相干
脈絡膜/病理生理學%脈絡膜新生血管化/藥物療法%血管生成抑製劑/治療應用%抗體,單剋隆/治療應用%體層攝影術,光學相榦
맥락막/병리생이학%맥락막신생혈관화/약물요법%혈관생성억제제/치료응용%항체,단극륭/치료응용%체층섭영술,광학상간
Choroid/physiopathology%Choroidal neovascularization/drug therapy%Angiogenesis inhibitors/therapeutic use%Antibodies,monoclonal/therapeutic use%Tomography,optical coherence
目的 观察玻璃体腔重复注射雷珠单抗对脉络膜新生血管(CNV)患眼脉络膜厚度(CT)的影响.方法 前瞻性、开放性无对照研究.临床确诊的渗出型老年性黄斑变性(AMD)患者31例31只眼(AMD组)以及病理性近视CNV患者33例33只眼(病理性近视组)纳入研究.所有患眼行玻璃体腔注射10 mg/ml的雷珠单抗0.05 ml(含雷珠单抗0.5 mg)治疗,之后每一个月随访1次,共随访6个月.AMD组、病理性近视组患眼平均注射次数分别为(4.23±1.33)、(2.27±0.88)次.治疗前及治疗后1、3、6个月,采用频域光相干断层扫描的增强深度成像技术测量患眼中心凹下CT.对比分析治疗前后患眼的CT变化.分析末次随访时CT降低值与注射次数的相关性.结果 治疗后l、3、6个月,AMD组患眼平均CT较治疗前分别降低了(9.68±11.02)、(12.58±11.04)、(13.84±11.67) μm.AMD组患眼治疗后1、3、6个月平均CT与治疗前比较,差异均有统计学意义(t=4.89、6.34、6.60,P＜0.001).病理性近视组患眼平均CT分别为(81.09±63.20)、(79.52±63.64)、(79.88±62.46) μm,较治疗前分别降低了(2.06±10.92)、(3.64±8.78)、(3.27±7.20)μm.病理性近视组患眼治疗后1个月平均CT与治疗前比较,差异无统计学意义(t=1.08,P=0.287);治疗后3、6个月平均CT与治疗前比较,差异均有统计学意义(t=2.38、2.61,P=0.024、0.014).相关性分析结果显示,AMD组、病理性近视组患眼末次随访时CT降低值与注射次数均无相关性(r=0.04、0.30,P=0.815、0.099).结论 玻璃体腔重复注射雷珠单抗会引起渗出型AMD及病理性近视CNV患眼的CT降低.
目的 觀察玻璃體腔重複註射雷珠單抗對脈絡膜新生血管(CNV)患眼脈絡膜厚度(CT)的影響.方法 前瞻性、開放性無對照研究.臨床確診的滲齣型老年性黃斑變性(AMD)患者31例31隻眼(AMD組)以及病理性近視CNV患者33例33隻眼(病理性近視組)納入研究.所有患眼行玻璃體腔註射10 mg/ml的雷珠單抗0.05 ml(含雷珠單抗0.5 mg)治療,之後每一箇月隨訪1次,共隨訪6箇月.AMD組、病理性近視組患眼平均註射次數分彆為(4.23±1.33)、(2.27±0.88)次.治療前及治療後1、3、6箇月,採用頻域光相榦斷層掃描的增彊深度成像技術測量患眼中心凹下CT.對比分析治療前後患眼的CT變化.分析末次隨訪時CT降低值與註射次數的相關性.結果 治療後l、3、6箇月,AMD組患眼平均CT較治療前分彆降低瞭(9.68±11.02)、(12.58±11.04)、(13.84±11.67) μm.AMD組患眼治療後1、3、6箇月平均CT與治療前比較,差異均有統計學意義(t=4.89、6.34、6.60,P＜0.001).病理性近視組患眼平均CT分彆為(81.09±63.20)、(79.52±63.64)、(79.88±62.46) μm,較治療前分彆降低瞭(2.06±10.92)、(3.64±8.78)、(3.27±7.20)μm.病理性近視組患眼治療後1箇月平均CT與治療前比較,差異無統計學意義(t=1.08,P=0.287);治療後3、6箇月平均CT與治療前比較,差異均有統計學意義(t=2.38、2.61,P=0.024、0.014).相關性分析結果顯示,AMD組、病理性近視組患眼末次隨訪時CT降低值與註射次數均無相關性(r=0.04、0.30,P=0.815、0.099).結論 玻璃體腔重複註射雷珠單抗會引起滲齣型AMD及病理性近視CNV患眼的CT降低.
목적 관찰파리체강중복주사뢰주단항대맥락막신생혈관(CNV)환안맥락막후도(CT)적영향.방법 전첨성、개방성무대조연구.림상학진적삼출형노년성황반변성(AMD)환자31례31지안(AMD조)이급병이성근시CNV환자33례33지안(병이성근시조)납입연구.소유환안행파리체강주사10 mg/ml적뢰주단항0.05 ml(함뢰주단항0.5 mg)치료,지후매일개월수방1차,공수방6개월.AMD조、병이성근시조환안평균주사차수분별위(4.23±1.33)、(2.27±0.88)차.치료전급치료후1、3、6개월,채용빈역광상간단층소묘적증강심도성상기술측량환안중심요하CT.대비분석치료전후환안적CT변화.분석말차수방시CT강저치여주사차수적상관성.결과 치료후l、3、6개월,AMD조환안평균CT교치료전분별강저료(9.68±11.02)、(12.58±11.04)、(13.84±11.67) μm.AMD조환안치료후1、3、6개월평균CT여치료전비교,차이균유통계학의의(t=4.89、6.34、6.60,P＜0.001).병이성근시조환안평균CT분별위(81.09±63.20)、(79.52±63.64)、(79.88±62.46) μm,교치료전분별강저료(2.06±10.92)、(3.64±8.78)、(3.27±7.20)μm.병이성근시조환안치료후1개월평균CT여치료전비교,차이무통계학의의(t=1.08,P=0.287);치료후3、6개월평균CT여치료전비교,차이균유통계학의의(t=2.38、2.61,P=0.024、0.014).상관성분석결과현시,AMD조、병이성근시조환안말차수방시CT강저치여주사차수균무상관성(r=0.04、0.30,P=0.815、0.099).결론 파리체강중복주사뢰주단항회인기삼출형AMD급병이성근시CNV환안적CT강저.
Objective To study changes in choroidal thickness(CT) with intravitreal injections of ranibizumab treatment.Methods This is a prospective,uncontrolled,open-label study.A total of 31 eyes of 31 patients diagnosed with wet age-related macular degeneration (AMD) and 33 eyes of 33 patients diagnosed with choroidal neovascularization (CNV) secondary to pathological myopia (PM) were included in the study.All affected eyes were treated with intravitreal ranibizumab 0.05 ml (10 mg/ml) and followed up monthly until 6 months.Enhanced depth imaging on Cirrus spectral-domain optical coherence tomography was used to measure the CT.The initial CT was compared with the data at 1,3 and 6 month after treatment,and the correlation between of the decrease of CT at the 6 month and the number of injection times was analyzed.Results In AMD group,the average CT respectively decreased by (9.68 ± 11.02),(12.58±11.04),(13.84± 11.67) μm at 1,3 and 6 month,and the differences were significant(t=4.89,6.34,6.60;P＜0.001).In PM group,the average CT respectively decreased by (2.06± 10.92),(3.64± 8.78),(3.27±7.20)μm at 1,3 and 6 month.The difference at 1 month was not significant (t=l.08,P=0.287).While after 3 months and 6 months,the differences were significant (t =2.38,2.61 ; P =0.024,0.014).The injection times were not correlated with the CT decreases at 6 month in both groups(r=0.04,0.30;P=0.815,0.099).Conclusion Intravitreal injections of ranibizumab can induce choroidal thickness reduction for wet age-related macular degeneration and choroidal neovascularization secondary to pathologic myopia.
